Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Frankfurt - Delayed Quote EUR

Penumbra, Inc. (0P8.F)

Compare
238.60
-6.50
(-2.65%)
At close: April 4 at 9:55:02 PM GMT+2
Loading Chart for 0P8.F
  • Previous Close 245.10
  • Open 244.60
  • Bid 238.30 x 6100
  • Ask 243.10 x 6100
  • Day's Range 235.70 - 244.60
  • 52 Week Range 97.86 - 291.60
  • Volume 21
  • Avg. Volume 0
  • Market Cap (intraday) 9.19B
  • Beta (5Y Monthly) 0.56
  • PE Ratio (TTM) 723.03
  • EPS (TTM) 0.33
  • Earnings Date Apr 23, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

www.penumbrainc.com

4,500

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 0P8.F

View More

Performance Overview: 0P8.F

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

0P8.F
5.02%
S&P 500 (^GSPC)
13.73%

1-Year Return

0P8.F
20.87%
S&P 500 (^GSPC)
1.42%

3-Year Return

0P8.F
19.30%
S&P 500 (^GSPC)
10.72%

5-Year Return

0P8.F
64.55%
S&P 500 (^GSPC)
103.89%

Compare To: 0P8.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 0P8.F

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    9.15B

  • Enterprise Value

    9.04B

  • Trailing P/E

    731.91

  • Forward P/E

    72.46

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    8.66

  • Price/Book (mrq)

    8.82

  • Enterprise Value/Revenue

    8.36

  • Enterprise Value/EBITDA

    217.12

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.17%

  • Return on Assets (ttm)

    4.84%

  • Return on Equity (ttm)

    1.20%

  • Revenue (ttm)

    1.19B

  • Net Income Avi to Common (ttm)

    14.01M

  • Diluted EPS (ttm)

    0.33

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    340.13M

  • Total Debt/Equity (mrq)

    19.41%

  • Levered Free Cash Flow (ttm)

    143.8M

Research Analysis: 0P8.F

View More

Company Insights: 0P8.F

Research Reports: 0P8.F

View More

People Also Watch